A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
about
A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
A consensus statement for the ...... with type 2 diabetes mellitus.
@en
A consensus statement for the ...... with type 2 diabetes mellitus.
@nl
type
label
A consensus statement for the ...... with type 2 diabetes mellitus.
@en
A consensus statement for the ...... with type 2 diabetes mellitus.
@nl
prefLabel
A consensus statement for the ...... with type 2 diabetes mellitus.
@en
A consensus statement for the ...... with type 2 diabetes mellitus.
@nl
P2093
P2860
P1476
A consensus statement for the ...... with type 2 diabetes mellitus
@en
P2093
A Giaccari
F Giorgino
F Purrello
P Fioretto
S Del Prato
P2860
P304
P356
10.1080/17512433.2017.1322507
P407
P50
P577
2017-05-02T00:00:00Z